Canada's Seniors Prefer High-Dose Quadrivalent Flu Shots

Sanofi Canada recently announced the National Advisory Committee on Immunization's annual Statement on Seasonal Influenza Vaccine for 2024-2025 continues to recommend Fluzone® High-Dose Quadrivalent among the preferential influenza vaccines to protect adults 65 years of age and older against influenza.

Delphine Lansac, General Manager, Vaccines Canada, Sanofi, commented in a press release on January 3, 2023, "This long-standing recommendation as a preferential influenza vaccine for adults 65 years of age and older speaks to the science that Fluzone® High-Dose Quadrivalent is built on and demonstrates our continued leadership in vaccines."

"It's been a groundbreaking year, where over 50% – more than one in two – seniors who received influenza vaccines in Canada were immunized with Fluzone® High-Dose Quadrivalent Influenza Vaccine."

Fluzone® High-Dose Quadrivalent Influenza Vaccine is designed to protect seniors with four times the active component dosage of a standard flu shot.

To date, Fluzone® High-Dose is available in more than 20 countries, including the United States, Canada, and Germany.

As of December 23, 2023, over 155 million flu shots had been distributed in the U.S. this season.